Skye Bioscience, Inc. (SKYE): Form 8-K filed 2026-09-11

Items reported

Item 1.02: Termination of a Material Definitive Agreement
A material agreement was terminated other than by expiring on its stated date. The company describes the agreement, the circumstances of the termination and any material early-termination penalties.
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed.
Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news.

Type	Description	Document
8-K	8-K	skye-20260908.htm

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.